1. Pink Sheet
  2. >>Geography

Infinity Extends R&D Collaboration With Mundipharma, Gets Another $50 Million For PI3K Program

Mundipharma has once again reinforced its partnership with Infinity by committing an additional $50 million to the partnership, with the money to be used in 2013 to support the biotech’s ongoing development of Hedgehog pathway inhibitor IPI-926.

Infinity Pharmaceuticals Inc. and Mundipharma International Corp. Ltd. have extended their R&D collaboration a second time, adding a $50 million commitment for 2013 to fund continued development of a dual phosphoinositide-3-kinase (PI3K) delta and gamma inhibitor for a range of indications.

The latest agreement, announced Nov. 29, adds to a 2008 collaboration that seemingly was modeled on the relationship between

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

US FDA’s Elsa AI Platform Is Not Guiding Regulatory Decisions, Official Says

 
• By Cathy Kelly

Tala Fakhouri said the agency’s use of the AI tool in the review process has generated lots of questions.

Branch Chief Vijay Kumar Named Acting Head Of US FDA’s Cell, Gene Therapy Office

 
• By Derrick Gingery

Kumar takes over as acting director of the Center for Biologics Evaluation and Research’s Office of Therapeutic Products days after director Nicole Verdun was ousted.

Recent And Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.